These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12200667)

  • 1. Effects of imatinib on bone marrow engraftment in syngeneic mice.
    Hoepfl J; Miething C; Grundler R; Götze KS; Peschel C; Duyster J
    Leukemia; 2002 Sep; 16(9):1584-8. PubMed ID: 12200667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
    Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
    Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
    Zong Y; Zhou S; Sorrentino BP
    Leukemia; 2005 Sep; 19(9):1590-6. PubMed ID: 16001089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
    Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
    Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
    Miething C; Feihl S; Mugler C; Grundler R; von Bubnoff N; Lordick F; Peschel C; Duyster J
    Leukemia; 2006 Apr; 20(4):650-7. PubMed ID: 16482207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of imatinib on haematopoietic recovery following idarubicin exposure.
    Ruchatz H; Puttini M; Cleris L; Pilotti S; Gambacorti-Passerini C; Formelli F
    Leukemia; 2003 Feb; 17(2):298-304. PubMed ID: 12592326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hoelzer D; Gökbuget N; Ottmann OG
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice.
    Down JD; Westerhof GR; Boudewijn A; Setroikromo R; Ploemacher RE
    Bone Marrow Transplant; 1998 Feb; 21(4):327-30. PubMed ID: 9509964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of imatinib on normal hematopoiesis and immune activation.
    Appel S; Balabanov S; Brümmendorf TH; Brossart P
    Stem Cells; 2005 Sep; 23(8):1082-8. PubMed ID: 16140870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.
    Balabanov S; Appel S; Kanz L; Brossart P; Brümmendorf TH
    Ann N Y Acad Sci; 2005 Jun; 1044():168-77. PubMed ID: 15958710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse in chronic myeloid leukemia after bone marrow transplantation: biomathematical modeling as a new approach to understanding pathogenesis.
    Vincent PC; Rutzen-Loesevitz L; Tibken B; Heinze B; Hofer EP; Fliedner TM
    Stem Cells; 1999; 17(1):9-17. PubMed ID: 10215403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
    Tam YK; Klingemann HG
    Biol Blood Marrow Transplant; 1999; 5(4):231-42. PubMed ID: 10465103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.